Jochen H Lorch

Jochen H Lorch is a Professor of Medicine specializing in Hematology and Oncology at the Feinberg School of Medicine, Northwestern University. His clinical and research focus centers on head and neck cancers, with particular expertise in thyroid malignancies and squamous cell carcinomas.

Dr. Lorch's research spans both basic science and clinical applications:

• Molecular mechanisms of cell adhesion and migration in head and neck cancers
• Immunotherapy approaches for advanced thyroid and nasopharyngeal carcinomas
• Combination therapies targeting EGFR and immune checkpoints
• Radiation treatment optimization for head and neck malignancies
• Biomarker development for treatment response prediction

His publication history reveals an evolution from fundamental cancer biology research toward clinical translation, with recent work heavily focused on immunotherapy applications for difficult-to-treat head and neck cancers. The 2022 publication on radiation dose effects demonstrates his continued interest in optimizing conventional treatments alongside novel therapeutic approaches.

Professional leadership includes:

• Co-chair of the International Thyroid Oncology Group (2024-Present)
• Scientific Advisory Board Chair at Flashpoint Therapeutics (2024-Present)
• Member of the American Thyroid Association (2015-Present)
• Member of ASCO (2003-Present)

Dr. Lorch serves as principal investigator for multiple active clinical trials investigating novel treatments including NRG HN011 (immunotherapy combinations for nasopharyngeal carcinoma), the TEMPUS PHOENIX HNSCC biomarker study, and a phase 2 trial of XL092 for radioiodine-refractory thyroid cancer. His industry relationships include consulting roles with Bluprint Oncology Concepts, Coherus BioSciences, Eisai, and Novartis.